28. June 2019 Friday

14:30 – 15:40 Lunch

15:45 – 16:00 Welcome address

Alicja Chybicka (Wroclaw),  Krzysztof Kałwak (Wroclaw)
Meinolf Suttorp (Dresden),  Petr Sedlacek (Prague)

16:00 – 17:30 Session 1
Rare diseases and new approaches

   Chair: Alexander Claviez (Kiel), Krzysztof Kałwak (Wroclaw)

Rare histiocytoses (20')
Carl Friedrich Classen (D)

Ph+ ALL or Ph+CML. What difference does it make? (20')
Markus Metzler (D)

Can children with CML stop imatinib? (20')
Meinolf Suttorp (D)

Checkpoint inhibitors in the treatment of pediatric lymphomas. Is there a breakthrough? (20')
Alexander Claviez (D)


17:30 – 18:00 Coffee Break

18:00 – 19:15 Session 2
Acute myeloid leukemia

   Chair: Ursula Creutzig (Hannover), Dirk Reinhardt (Essen)

CPX351 (Vyxeos) in the treatment of adult and pediatric AML (20')
Dirk Reinhardt (D)

Secondary AML – a distinct entity or not? (20')
Ursula Creutzig (D)

Cytomegalovirus reactivation in pediatric acute leukemia after stem cell transplantation has an effect on relapse and survival in AML but not in B-precursor ALL (20')
Sebastian Voigt (D)


19:30 – Networking Dinner

29. June 2019 Saturday

08:30 – 09:45 Session 3
Acute lymphoblastic leukemia

   Chair: Carl Friedrich Classen (Rostock), Meinolf Suttorp (Dresden)

Unique clinical course of pediatric ALL among carriers of germline mutation in the NBN gene (20')
Wojciech Młynarski (PL)

MRD: Flow vs PCR (20')
Tomasz Szczepański (PL)

Mice exposed to germ-free conditions and the risk of ALL (20')
Julia Hauer (D)


09:45 – 10:00 Coffee Break

10:00 – 12:15 Session 4
The broad field of pediatric stem cell transplantation

   Chair: Jacek Wachowiak (Poznan), Petr Sedlacek (CZ)

MAS after HSCT (20')
Petr Sedlacek (CZ)

Allogeneic HSCT for BCR/ABL - negative MPNs in children (20')
Jacek Wachowiak (PL)

The importance of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation (20')
Bernd Gruhn (D)

Bu MEL conditioning in neuroblastoma and its associated risk of VOD (20')
Tomas Sykora (SK)

Conception and parenting after HSCT. Is it a realistic option? (20')
Petr Sedlacek (CZ)

The role of KIRs in donor matching (20')
Marek Ussowicz (PL)


12:15 – 13:30 Lunch

13:30 – 15:00 Session 5
HSCT in non–malignant disorders

   Chair: Marek Ussowicz (Wroclaw), Markus Metzler (Erlangen)

Post-transplant B-cell reconstitution in patients with B-positive SCID (20')
Manfred Hoenig (D)

Mutations in PID: from DNA to function (20')
Ulrich Pannicke (D)

The natural history of cancer in Nijmegen breakage syndrome: defining the interference of haematopoietic stem cell transplantation (20')
Agata Pastorczak (PL)

RECOMB – stem cell gene therapy in RAG-deficient SCID patients (20')
Monika Mielcarek-Siedziuk, Krzysztof Kałwak (PL)


15.00 – 16.00 Session 6
Cord blood and Wharton’s Jelly derived MSCs

   Chair: Bernd Gruhn (Jena), Krzysztof Kałwak (Wroclaw)

Autologous and allogeneic CBT in autism, cerebral palsy and other disorders – a hype or hope? (20')
Krzysztof Kałwak (PL)

Mesenchymal Stem Cells i.v. and i.t. in neurology Case studies (20')
Magdalena Chrościńska–Krawczyk (PL)


16:00 – 16:30 Coffee Break

16:30 – 18:30 Session 7
“Pretty Kettle of Fish” – Eine schöne Bescherung
No to pięknie! – To je ale nadělení!
Ez aztán szép kis meglepetés! – Čo sa to tu deje?

   Chair: Krzysztof Kałwak (Wroclaw), Meinolf Suttorp (Dresden)

Post- transplant twister-blister (15’)
Linda-Marie Mulzer (D)

Unique NUP214-ABL1 fusion origin in BCP-ALL: a therapeutic implication (15')
Joanna Taha (PL)

Same, same, but different! (15’)
Ruth Deindl (D)

Unilateral pleural effusion - first symptom of an extramedullary AML with myelon compression in an infant (15’)
Ricardo Beck (D)

Hematopoietic stem cell transplantation in a girl with sideroblastic anemia – complex medical care in rare disease (15’)
Agnieszka Pomykała-Słupianek (PL)

Diagnostic and therapeutic difficulties in patient with bone marrow proliferative disease (15’)
Krzysztof Czyżewski (PL)


19:45 – Dinner

30. June 2019 Sunday

09:00 – 10:00 Session 8
Novel therapies in ALL and NHL

   Chair: Sebastian Voigt (Berlin), Tomasz Szczepański (Zabrze),

Blinatumomab and/or Inotuzumab ozogamycin. Global and Prague experience (20')
Lucie Sramkova (CZ)

CAR-T cells in the treatment of B-cell ALL (20')
Krzysztof Kałwak (PL)


10:00 – 11:30 Session 9
Infectious complications in pediatric hematooncology

   Chair: Gergely Krivan (Budapest), Wojciech Młynarski (Lodz)

Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplant Recipients: Findings from the AdVance Study. The role of brincidofovir in the treatment of refractory infections (20')
Sebastian Voigt (D)

CMV, ADV and EBV-specific T cells – lessons from Budapest (20')
Gergely Krivan (H)

What’s new in the prophylaxis of fungal infections? (20')
Krzysztof Kałwak (PL)

Isavuconazole - new powerful drug in the treatment of IFD - recommendations + personal experience (20')
Anna Pomorska (PL)


11:30 – 11:45 Coffee Break

11:45 – 13:00 Session 10
From bench and bedside
(Abstracts of young and more experienced investigators selected for oral presentation)
   Chair: Petr Sedlacek (Prague), Meinolf Suttorp (Dresden)

Hurler syndrome and lymphoma (15')
Anna Toth (HU)

Successful use of eculizumab in a patient with dialysis-dependent aHUS after HSCT (20')
Tomasz Jarmoliński (PL)

Introduction of new pediatric EBMT criteria for VOD diagnosis: is it life-saving or money-wasting? (20')
Zofia Szmit (PL)

The preferred therapy in a 15- year old boy with Netherton syndrome and acute lymphoblastic leukemia with JAK2 mutation (15’)
Szymon Skoczeń (PL)


13.00 – 14.00 Lunch